推荐产品
品質等級
形狀
buffered aqueous glycerol solution
分子量
59 kDa
濃度
600-1,000 units/mL pyruvate kinase
900-1400 units/mL lactic dehydrogenase
儲存溫度
−20°C
一般說明
兔肌丙酮酸激酶是一种金属酶，可用于在糖酵解途径中催化磷酸烯醇丙酮酸转化为丙酮酸。它的分子量为59 kDa。它以四聚体的形式存在，其活性部位发生构型变化以适应底物。乳酸脱氢酶(LDH)在无氧糖酵解中催化乳酸转化为丙酮酸。它以四聚体的形式存在，由两个亚基（H和M）组成。真核生物的LDH通过活性位点循环门控实现催化功能。
應用
兔肌来源丙酮酸激酶/乳酸脱氢酶可用于：
- 在活性微管制备中产生ATP
- 骨骼肌重酶解肌球蛋白(HMM)的酶联ATP酶测定
- 作为量化间充质干细胞(MSC)乳酸脱氢酶的标准对照品。
生化／生理作用
在测定ADP中使用PK/LDH的ADP定量检测方案。 在该方案中，含有未知浓度ADP的溶液可代替试剂D。可能需要进一步稀释ADP溶液
丙酮酸激酶进行活化分别需要二价和一价阳离子（如Mg2+和K+）。
抗坏血酸可抑制兔肌肉乳酸脱氢酶。醛缩酶和肌动蛋白被证明可以阻断这种抑制作用。
此外，丙酮酸激酶还可催化二磷酸硫胺磷酸化(TDP)为三磷酸硫胺素(TTP)，可应用于抗病毒和肿瘤治疗。
單位定義
丙酮酸激酶活性：在pH7.6，37℃下，一单位酶每分钟可将1.0 μmole的磷酸（烯醇）丙酮酸转化为丙酮酸。
乳酸脱氢酶活性：在pH7.5，37℃下，一单位酶每分钟可将1.0 μmole丙酮酸盐还原为L-乳酸盐。
乳酸脱氢酶活性：在pH7.5，37℃下，一单位酶每分钟可将1.0 μmole丙酮酸盐还原为L-乳酸盐。
外觀
含有10mM HEPES，pH 7.0，100mM KCl和0.1mM EDTA的50％甘油溶液
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
其他客户在看
Linnea M Lemma et al.
Soft matter, 15(15), 3264-3272 (2019-03-29)
We study the dynamics of a tunable 2D active nematic liquid crystal composed of microtubules and kinesin motors confined to an oil-water interface. Kinesin motors continuously inject mechanical energy into the system through ATP hydrolysis, powering the relative microscopic sliding
Ligand-Induced Domain Movement in Pyruvate Kinase: Structure of the Enzyme from Rabbit Muscle with Mg2+, K+, and l-Phospholactate at 2.7 AA Resolution
Larsen TM, et al.
Archives of Biochemistry and Biophysics, 345(2), 199-206 (1997)
Roxana E Iacob et al.
PloS one, 6(1), e15929-e15929 (2011-01-26)
Abl kinase inhibitors targeting the ATP binding pocket are currently employed as potent anti-leukemogenic agents but drug resistance has become a significant clinical limitation. Recently, a compound that binds to the myristate pocket of Abl (GNF-5) was shown to act
Cai-Hong Yun et al.
Proceedings of the National Academy of Sciences of the United States of America, 105(6), 2070-2075 (2008-01-30)
Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small molecule tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred
Jianming Zhang et al.
Nature, 463(7280), 501-506 (2010-01-15)
In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor. Here, using solution NMR, X-ray crystallography, mutagenesis and hydrogen exchange mass spectrometry
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门